{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:24:46Z","timestamp":1777465486800,"version":"3.51.4"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014387","name":"Acadia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Alkermes"},{"name":"AssureX"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014930","name":"Arbor Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014930","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Avanir"},{"name":"Axovant"},{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Braeburn Pharmaceuticals"},{"name":"BristolMyer Squibb"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006437","name":"CeNeRx","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006437","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004388","name":"Cephalon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004388","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Dey"},{"DOI":"10.13039\/100004312","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EnVivo"},{"DOI":"10.13039\/100005632","name":"Forest","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005632","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Forum"},{"name":"GenOmind"},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Intra-Cellular Therapies"},{"name":"ISSWSH"},{"DOI":"10.13039\/100008897","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"JayMac"},{"DOI":"10.13039\/100011096","name":"Jazz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mylan"},{"DOI":"10.13039\/100014593","name":"Neurocrine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014593","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Neuronetics"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PamLabs"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Reviva"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009654","name":"Sepracor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009654","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sprout"},{"DOI":"10.13039\/100009655","name":"Sunovion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009655","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TMS NeuroHealth Centers"},{"name":"Takeda"},{"DOI":"10.13039\/100006259","name":"Teva","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Tonix"},{"DOI":"10.13039\/100010902","name":"Vanda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010902","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011284","name":"Valeant","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011284","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004342","name":"Wyeth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.psc.2019.10.015","type":"journal-article","created":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T08:46:36Z","timestamp":1575362796000},"page":"167-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pharmacologic Treatment of Mixed States"],"prefix":"10.1016","volume":"43","author":[{"given":"Maurizio","family":"Pompili","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo H.","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Forte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbi Ann","family":"Morrissette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.psc.2019.10.015_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"issue":"9","key":"10.1016\/j.psc.2019.10.015_bib2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can J Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2019.10.015_bib3","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/15622970903555881","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression","volume":"11","author":"Grunze","year":"2010","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0269881109102919","article-title":"Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology","volume":"23","author":"Goodwin","year":"2009","journal-title":"J\u00a0Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/15622975.2017.1384850","article-title":"The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: acute and long-term treatment of mixed states in bipolar disorder","volume":"19","author":"Grunze","year":"2018","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.psc.2019.10.015_bib6","series-title":"Diagnostic and statistical manual of mental disorders, 5th edition (DSM-5)","first-page":"280","year":"2013"},{"issue":"2","key":"10.1016\/j.psc.2019.10.015_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1017\/S1092852917000165","article-title":"Guidelines for the recognition and management of mixed depression","volume":"22","author":"Stahl","year":"2017","journal-title":"CNS Spectr"},{"issue":"5","key":"10.1016\/j.psc.2019.10.015_bib8","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/15622975.2014.908238","article-title":"Clinical decision making in the treatment of mixed states","volume":"15","author":"Grunze","year":"2014","journal-title":"World J Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/acps.12911","article-title":"Characteristics of depressive and bipolar disorder patients with mixed features","volume":"138","author":"Tondo","year":"2018","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/acps.12896","article-title":"Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines","volume":"138","author":"Verdolini","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.psc.2019.10.015_bib11","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jad.2017.09.006","article-title":"Mixed symptoms in major depressive and bipolar disorders: a systematic review","volume":"225","author":"V\u00e1zquez","year":"2018","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.psc.2019.10.015_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jad.2015.06.059","article-title":"Asenapine: efficacy and safety of 5 and 10\u00a0mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder","volume":"190","author":"Landbloom","year":"2016","journal-title":"J\u00a0Affect Disord"},{"issue":"7","key":"10.1016\/j.psc.2019.10.015_bib13","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","article-title":"A\u00a03-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disord"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jad.2012.01.047","article-title":"A\u00a0randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode","volume":"138","author":"Berwaerts","year":"2012","journal-title":"J\u00a0Affect Disord"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib15","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881106059693","article-title":"Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study","volume":"20","author":"Sachs","year":"2006","journal-title":"J\u00a0Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2019.10.015_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/ajp.156.5.702","article-title":"Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group","volume":"156","author":"Tohen","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-5618.2010.00815.x","article-title":"A\u00a0randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder","volume":"12","author":"Vieta","year":"2010","journal-title":"Bipolar Disord"},{"issue":"11","key":"10.1016\/j.psc.2019.10.015_bib18","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.clinthera.2011.10.002","article-title":"Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial","volume":"33","author":"Cutler","year":"2011","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib19","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"9","key":"10.1016\/j.psc.2019.10.015_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/archpsyc.57.9.841","article-title":"Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group","volume":"57","author":"Tohen","year":"2000","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib21","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/JCP.0000000000000323","article-title":"A\u00a013-week, randomized double-blind, placebo-controlled, cross-over trial of ziprasidone in bipolar spectrum disorder","volume":"35","author":"Patkar","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1176\/appi.ajp.2015.15060770","article-title":"Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study","volume":"173","author":"Suppes","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.psc.2019.10.015_bib23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jad.2014.04.003","article-title":"Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features","volume":"164","author":"Tohen","year":"2014","journal-title":"J\u00a0Affect Disord"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4088\/JCP.14m09410","article-title":"Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial","volume":"76","author":"McIntyre","year":"2015","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib25","doi-asserted-by":"crossref","first-page":"e34757","DOI":"10.1371\/journal.pone.0034757","article-title":"A\u00a06\u00a0week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. Mazza M, ed","volume":"7","author":"Patkar","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jad.2013.02.031","article-title":"First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo","volume":"150","author":"Suppes","year":"2013","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.psc.2019.10.015_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jad.2019.07.020","article-title":"Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials","volume":"257","author":"McIntyre","year":"2019","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.psc.2019.10.015_bib28","first-page":"1","article-title":"The use of lithium in mixed states","author":"Sani","year":"2019","journal-title":"CNS Spectr"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.eurpsy.2008.12.009","article-title":"Identifying predictors for good lithium response - a retrospective analysis of 100 patients with bipolar disorder using a life-charting method","volume":"24","author":"Backlund","year":"2009","journal-title":"Eur Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1192\/bjp.bp.110.084822","article-title":"Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study","volume":"199","author":"Kessing","year":"2011","journal-title":"Br J Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2019.10.015_bib31","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.4088\/JCP.11m06878","article-title":"Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of Bipolar I Disorder","volume":"72","author":"Weisler","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bdi.12027","article-title":"The association of the effect of lithium in the maintenance treatment of bipolar disorder with lithium plasma levels: a post hoc analysis of a double-blind study comparing switching to lithium or placebo in patients who responded to quetiapine (Trial 144)","volume":"15","author":"Nolen","year":"2013","journal-title":"Bipolar Disord"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib33","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","article-title":"Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy","volume":"59","author":"Tohen","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"10.1016\/j.psc.2019.10.015_bib34","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1192\/bjp.185.6.472","article-title":"Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania","volume":"185","author":"Baker","year":"2004","journal-title":"Br J Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.psc.2019.10.015_bib35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jad.2010.09.011","article-title":"Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study","volume":"129","author":"Berwaerts","year":"2011","journal-title":"J\u00a0Affect Disord"},{"issue":"12","key":"10.1016\/j.psc.2019.10.015_bib36","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.1994.03510360044034","article-title":"Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group","volume":"271","author":"Bowden","year":"1994","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/archpsyc.1997.01830130041008","article-title":"Depression during mania. Treatment response to lithium or divalproex","volume":"54","author":"Swann","year":"1997","journal-title":"Arch Gen Psychiatry"},{"issue":"5 Pt 2","key":"10.1016\/j.psc.2019.10.015_bib38","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1399-5618.2006.00344.x","article-title":"Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review","volume":"8","author":"Baldessarini","year":"2006","journal-title":"Bipolar Disord"},{"issue":"10","key":"10.1016\/j.psc.2019.10.015_bib39","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.npp.1300788","article-title":"Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo","volume":"30","author":"Bowden","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1176\/ajp.149.1.108","article-title":"A\u00a0double-blind comparison of valproate and lithium in the treatment of acute mania","volume":"149","author":"Freeman","year":"1992","journal-title":"Am J Psychiatry"},{"issue":"10","key":"10.1016\/j.psc.2019.10.015_bib41","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.4088\/JCP.v67n1003","article-title":"A\u00a0randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania","volume":"67","author":"Bowden","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.psc.2019.10.015_bib42","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jad.2012.11.042","article-title":"Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode","volume":"147","author":"Yatham","year":"2013","journal-title":"J\u00a0Affect Disord"},{"issue":"1\u20133","key":"10.1016\/j.psc.2019.10.015_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jad.2012.04.014","article-title":"Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder","volume":"142","author":"Vieta","year":"2012","journal-title":"J\u00a0Affect Disord"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib44","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","article-title":"Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)","volume":"109","author":"Vieta","year":"2008","journal-title":"J\u00a0Affect Disord"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib45","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2008.08020189","article-title":"Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127)","volume":"166","author":"Suppes","year":"2009","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00004714-199908000-00003","article-title":"Intravenous valproate loading in acutely manic and depressed bipolar I patients","volume":"19","author":"Grunze","year":"1999","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib47","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/WNF.0000000000000265","article-title":"Intravenous valproic acid add-on therapy in acute agitation adolescents with suspected substance abuse","volume":"41","author":"Battaglia","year":"2018","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.psc.2019.10.015_bib48","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/archgenpsychiatry.2011.1508","article-title":"A\u00a0randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of Bipolar I Disorder, manic or mixed phase, in children and adolescents","volume":"69","author":"Geller","year":"2012","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.psc.2019.10.015_bib49","doi-asserted-by":"crossref","first-page":"pyw109","DOI":"10.1093\/ijnp\/pyw109","article-title":"The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for Bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines","volume":"20","author":"Fountoulakis","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"issue":"5","key":"10.1016\/j.psc.2019.10.015_bib50","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/0091270011404028","article-title":"Valproate reduces the glucuronidation of asenapine without affecting asenapine plasma concentrations","volume":"52","author":"Gerrits","year":"2012","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib51","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4088\/JCP.v65n0405","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes","volume":"65","author":"Weisler","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib52","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4088\/JCP.v66n0308","article-title":"Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Weisler","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2019.10.015_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00023210-200620030-00004","article-title":"Extended-release carbamazepine capsules as monotherapy in bipolar disorder\u202f: pooled results from two randomised, double-blind, placebo-controlled trials","volume":"20","author":"Weisler","year":"2006","journal-title":"CNS Drugs"},{"issue":"1\u20133","key":"10.1016\/j.psc.2019.10.015_bib54","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0165-0327(02)00407-X","article-title":"Oxcarbazepine as add-on treatment in patients with bipolar manic, mixed or depressive episode","volume":"79","author":"Benedetti","year":"2004","journal-title":"J\u00a0Affect Disord"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib55","article-title":"The clinical management of bipolar disorder: a review of evidence-based guidelines","volume":"13","author":"Connolly","year":"2011","journal-title":"Prim Care Companion CNS Disord"},{"issue":"2\u20133","key":"10.1016\/j.psc.2019.10.015_bib56","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0165-0327(98)00110-4","article-title":"Use of topiramate, a new anti-epileptic as a mood stabilizer","volume":"50","author":"Marcotte","year":"1998","journal-title":"J\u00a0Affect Disord"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1034\/j.1399-5618.1999.10111.x","article-title":"Topiramate as add-on treatment for patients with bipolar mania","volume":"1","author":"Chengappa","year":"1999","journal-title":"Bipolar Disord"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib58","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1017\/S1092852913000102","article-title":"A\u00a0systematic review of the evidence for the treatment of acute depression in bipolar I disorder","volume":"18","author":"Cerullo","year":"2013","journal-title":"CNS Spectr"},{"issue":"5","key":"10.1016\/j.psc.2019.10.015_bib59","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating\u00a0depressive disorders with antidepressants: a revision of the 2008 British\u00a0Association for Psychopharmacology guidelines. Nutt DJ, Blier P, eds","volume":"29","author":"Cleare","year":"2015","journal-title":"J\u00a0Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000358808","article-title":"Mixed depression: clinical features and predictors of its onset associated with antidepressant use","volume":"83","author":"Sani","year":"2014","journal-title":"Psychother Psychosom"},{"issue":"2","key":"10.1016\/j.psc.2019.10.015_bib61","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1017\/neu.2015.52","article-title":"Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study","volume":"28","author":"Bj\u00f8rklund","year":"2016","journal-title":"Acta Neuropsychiatr"},{"issue":"9","key":"10.1016\/j.psc.2019.10.015_bib62","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1176\/appi.ajp.161.9.1537","article-title":"Antidepressants for bipolar depression: a systematic review of randomized, controlled trials","volume":"161","author":"Gijsman","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2019.10.015_bib63","doi-asserted-by":"crossref","first-page":"e008341","DOI":"10.1136\/bmjopen-2015-008341","article-title":"Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study","volume":"5","author":"Patel","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.psc.2019.10.015_bib64","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4088\/JCP.08m04191","article-title":"Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study","volume":"70","author":"Altshuler","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2019.10.015_bib65","doi-asserted-by":"crossref","first-page":"671","DOI":"10.4088\/JCP.09m05483yel","article-title":"Poor long-term prognosis in mixed bipolar patients: 10-year outcomes in the Vitoria prospective naturalistic study in Spain","volume":"72","author":"Gonz\u00e1lez-Pinto","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2019.10.015_bib66","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1176\/appi.ajp.2012.12030301","article-title":"Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis","volume":"170","author":"Swann","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"Suppl 2","key":"10.1016\/j.psc.2019.10.015_bib67","doi-asserted-by":"crossref","first-page":"II72","DOI":"10.1007\/BF03035132","article-title":"Arguments for the specificity of the antisuicidal effect of lithium","volume":"251","author":"M\u00fcller-Oerlinghausen","year":"2001","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.psc.2019.10.015_bib68","series-title":"Manic-depressive insanity and paranoia","author":"Kraepelin","year":"1921"},{"issue":"8","key":"10.1016\/j.psc.2019.10.015_bib69","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2165\/00023210-200721080-00001","article-title":"Epidemiology, diagnosis and management of mixed mania","volume":"21","author":"Gonzalez-Pinto","year":"2007","journal-title":"CNS Drugs"},{"issue":"2\u20133","key":"10.1016\/j.psc.2019.10.015_bib70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0165-0327(98)00113-X","article-title":"Gender, temperament, and the clinical picture in dysphoric mixed mania: findings from a French national study (EPIMAN)","volume":"50","author":"Akiskal","year":"1998","journal-title":"J\u00a0Affect Disord"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X19301108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X19301108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T01:39:48Z","timestamp":1759282788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X19301108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0193953X19301108"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2019.10.015","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic Treatment of Mixed States","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2019.10.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}